Epigenomics AG Licenses Biomarker for Development of Prostate Cancer Test to Quest Diagnostics

--------------------------------------------------------------------------------
ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for
the content of this announcement.
--------------------------------------------------------------------------------

cooperations/Molecular Diagnostics

Berlin, Germany and Seattle, WA, U.S.A. (euro adhoc) - February 25,
2009 - Epigenomics AG (Frankfurt, Prime Standard: ECX), a cancer
molecular diagnostics company, today announced that it has entered
into a non-exclusive licensing agreement for its proprietary
biomarker mGSTP1 with U.S.-based Quest Diagnostics Incorporated
(NYSE: DGX), the world's leading provider of diagnostic testing,
information and services.

Under the agreement, Quest Diagnostics has obtained rights to uses of
the GSTP1 DNA methylation biomarker (mGSTP1) to establish and
commercialize a molecular- based laboratory-developed test that can
help pathologists better diagnose prostate cancer based on testing of
a patient's tissue specimen. Financial terms were not disclosed.

Prostate cancer is the leading cause of cancer death in men in the
U.S., with more than 230,000 cases diagnosed annually. Epigenomics
and others have demonstrated that methylated DNA of the GSTP1 gene in
tissue may indicate the presence of prostate cancer. A test that
detects the DNA methylation of the gene GSTP1 in tissue biopsies in
combination with conventional histopathology may augment the accuracy
of prostate cancer diagnosis in particular in cases with suspicious
but inconclusive histology findings or patients with elevated PSA but
repeatedly negative biopsies.

Quest Diagnostics' experience in DNA methylation diagnostics includes
offering tests for Prader-Willi and Angelman Syndromes, two
neurologic epigenetic disorders that may be caused by faulty DNA
methylation. In 2008, Quest Diagnostics licensed rights to use
Epigenomics' proprietary colorectal cancer biomarker mSEPT9 to
develop and validate a blood-based laboratory-developed test as an
aid in the detection of colorectal cancer.

"We are pleased that Quest Diagnostics is expanding its menu of DNA
methylation tests using our technologies and biomarkers. Quest
Diagnostics has a strong record of innovation in diagnostics,
including development of other DNA methylation diagnostic tests. They
also share our goal to develop technologies that will help physicians
achieve improved health outcomes for their patients through better
diagnosis of prostate cancer and early detection of colorectal
cancer", said Geert Nygaard, Chief Executive Officer of Epigenomics.

About Epigenomics

Epigenomics is a molecular diagnostics company with a focus on the
development of novel products for cancer. Using DNA methylation
biomarkers, Epigenomics' tests in development aim at diagnosing
cancer at an early stage before symptoms occur and thereby may reduce
mortality from this dreaded disease.

Epigenomics' product pipeline contains a validated biomarker for the
early detection of colorectal cancer in blood plasma, and further
proprietary DNA methylation biomarkers at various stages of
development for prostate and lung cancer detection in urine, blood
and bronchial lavage specimens. Epigenomics' biomarker mSEPT9 for the
early detection of colorectal cancer in a simple blood sample
demonstrated continuously highest performance in multiple clinical
studies with in total about 3,500 individuals tested.

For development and global commercialization of in vitro diagnostic
test products, Epigenomics pursues a non-exclusive partnering
strategy. Strategic diagnostics industry partners include Abbott
Molecular, Philips, Sysmex Corporation and Quest Diagnostics
Incorporated for diagnostics test products and services, and QIAGEN
N.V. for sample preparation solutions and research products.

Partners in the health care industry and the biomedical research
community can access Epigenomics' portfolio of proprietary DNA
methylation technologies and biomarkers protected by more than 150
patent families through research products, Biomarker Services, IVD
Development Collaborations, and Licensing. The company is
headquartered in Berlin, Germany, and has a wholly owned subsidiary
in Seattle, WA, U.S.A. For more information, please visit
Epigenomics' website at www.epigenomics.com.

Epigenomics' legal disclaimer: This communication expressly or
implicitly contains certain forward-looking statements concerning
Epigenomics AG and its business. Such statements involve certain
known and unknown risks, uncertainties and other factors which could
cause the actual results, financial condition, performance or
achievements of Epigenomics AG to be materially different from any
future results, performance or achievements expressed or implied by
such forward-looking statements. Epigenomics AG is providing this
communication as of this date and does not undertake to update any
forward- looking statements contained herein as a result of new
information, future events or otherwise.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Epigenomics AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Dr. Achim Plum

Sen. VP Corporate Development

Epigenomics AG

Tel: +49 30 24345 368

achim.plum@epigenomics.com

Branche: Biotechnology
ISIN: DE000A0BVT96
WKN: A0BVT9
Index: Prime All Share, Technologie All Share
Börsen: Börse Frankfurt / regulated dealing/prime standard
Börse Berlin / free trade
Börse Hamburg / free trade
Börse Stuttgart / free trade
Börse Düsseldorf / free trade
Börse München / free trade